The company plans to launch 14 products in Brazil, targeting a potential market of USD 2 billion, expanding access to high-complexity treatments in key therapeutic areas, expecting to generate over USD 130 million in sales within the next 4 years. Through strategic...
CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. This marks CStone’s third major global commercialization partnership for...
Haemoctin® becomes the company’s first biological product in the plasma-derived segment, offering a cost-effective alternative for the treatment of hemophilia in the region. This partnership reinforces SteinCares’ leadership in expanding access to...
The acquisition strengthens SteinCares’ leadership and operations in the country and is expected to contribute to the subsidiary’s growth. The deal includes the marketing and distribution license for a treatment for severe pain. San Jose, Costa Rica,...
SteinCares has strengthened its product portfolio in Colombia through an expanded agreement with Pharmacosmos for the commercialization and distribution of Monofer®, an innovative intravenous iron replacement therapy. This alliance reinforces SteinCares’...
